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Objective: Type 2 diabetes mellitus (T2DM) is associated with elevated plasma apolipoprotein B and
triglycerides levels, reduced HDL cholesterol and the presence of small-dense LDL particles. The present
study was conducted to investigate the role of plasma proprotein convertase subtilisin kexin type 9
(PCSK9) levels, a regulator of LDL-receptor expression, in the occurrence of diabetic dyslipidemia.
Methods: Plasma PCSK9 was measured in a cohort of subjects with normal glucose metabolism (NGM;
n=288), impaired glucose metabolism (IGM; n=121) and type 2 diabetes mellitus (T2DM; n=139)
to study whether its relation with plasma apolipoprotein B, triglycerides, total cholesterol, non-HDL
cholesterol, LDL cholesterol and HDL cholesterol differed by levels of glucose metabolism status.
Results: Plasma PCSK9 levels were not different between the three groups (82, 82 and 80ng/mL in NGM,
IGM and T2DM, respectively). PCSK9 was positively associated with total cholesterol, non-HDL choles-
terol, LDL cholesterol, apolipoprotein B and triglycerides levels in all subgroups. The regression slopes
for the associations with non-HDL cholesterol were steeper among individuals with T2DM than with
NGM (ˇ =0.016 versus ˇ =0.009, p-interaction=0.05). Similar results were obtained for the relation with
apolipoprotein B (ˇ =0.004 versus ˇ =0.002, p-interaction=0.09).
Conclusions: Although glucose metabolism status per se is not associated with plasma PCSK9 levels,
the presence of T2DM may modify the relation between plasma PCSK9 and non-HDL cholesterol and
apolipoprotein B. These observations should be regarded as hypothesis generating for further studies
role oaimed at elucidating the
. Introduction
Patientswith type2diabetesmellitus (T2DM) frequentlydisplay
typical dyslipidemia – often referred to as diabetic dyslipidemia
that is characterized by elevated plasma apolipoprotein B and
riglycerides levels, reduced HDL cholesterol and the presence
f small-dense LDL particles, which is an important determi-
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ax: +31 0 43 367 09 16.
E-mail address: martijn.brouwers@maastrichtuniversity.nl (M.C.G.J. Brouwers).
021-9150 © 2011 Elsevier Ireland Ltd.
oi:10.1016/j.atherosclerosis.2011.03.023
Open access under the Elsevier OA license.f PCSK9 in the pathogenesis and treatment of diabetic dyslipidemia.
© 2011 Elsevier Ireland Ltd.
nant of macrovascular complications [1]. Stable isotope studies
have demonstrated that VLDL overproduction, at a background of
hepatic steatosis and insulin resistance, is one of the pathophysio-
logical hallmarks of diabetic dyslipidemia [2,3]. In addition, there
is evidence that the fractional catabolic rate of LDL particles is
impaired in patients with T2DM [4,5], which has been attributed
to a decreased LDL receptor expression [6]. However, the exact role
and regulation of the LDL receptor in relation to diabetic dyslipi-
demia has not been extensively studied, given the elaborate and
Open access under the Elsevier OA license.expensive nature of stable isotope studies.
Proprotein convertase subtilisin kexin type 9 (PCSK9) is an
important regulator of LDL receptor expression. It promotes the
degradation of the LDL receptor in hepatocytes by two differ-
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nt pathways, either intracellularly or as a systemically secreted
rotein that binds the LDL receptor, resulting in a combined inter-
alization and subsequent degradation [7]. A high expression of
CSK9 is therefore positively associated with plasma LDL choles-
erol levels [7].
The systemic release of PCSK9 enables its plasma measurement
n large cohort studies, which can be used to gain more insight in
he effect of PCSK9 on lipoprotein metabolism in speciﬁc disease
ntities, such as T2DM. Indeed, previous epidemiological studies
ave reported a relation between plasma PCSK9 levels and plasma
lucose and insulin, suggesting a role for PCSK9 in T2DM [8,9].
owever, these studies did not speciﬁcally address whether the
ole of plasma PCSK9 in relation to plasma lipids differs between
ndividualswithT2DMorat risk for T2DMand thosewithout T2DM.
The aim of this study was therefore to compare plasma PCSK9
evels between subjects with a broad spectrum of glucose tol-
rance, i.e. normal glucose metabolism (NGM), impaired glucose
etabolism (IGM) and T2DM. Given the previously reported pos-
tive relation with plasma glucose [8,9], we hypothesized that
lasma PCSK9 levels increase as glucose metabolism deteriorates.
n addition, we questioned whether the relation between circulat-
ng PCSK9 levels and plasma lipid levels differed according to the
egree of disturbed glucose metabolism.
. Methods
.1. Subjects and study design
Subjects were participants of the Cohort on Diabetes and
therosclerosis Maastricht (CODAM) study, an ongoing prospec-
ive cohort study in the Netherlands that was originally designed
o study the effects of obesity, glucose tolerance, lipid metabolism,
ifestyle and genetics on cardiovascular complications [10]. Brieﬂy,
etween 1999 and 2001 subjects were selected from a large
opulation-based cohort and included if they were of Caucasian
thnicity and aged above 40 years and had at least one of the fol-
owing: body mass index (BMI) >25kg/m2, positive family history
or T2DM, history of gestational diabetes, use of antihypertensive
edication, postprandial glucose >6.0mmol/L and glucosuria [10].
he original cohort included 574 subjects [10].
All subjects were subsequently asked to stop any lipid-lowering
edication two weeks prior to their visit to the University’s
esearch unit where blood withdrawals took place; glucose-
owering drugs were stopped on this visit day. Nineteen subjects
id notwithstanding continue their lipid-lowering medication.
iven the well-documented scattering effects of lipid-lowering
herapy on the relation between plasma PCSK9 levels and plasma
ipids [11], which was the primary focus of the current study, these
ubjectswereexcluded fromthis study. Inaddition, levelsofplasma
CSK9 were not obtained in 7 subjects. All analyses in the cur-
ent study were therefore conducted in 548 subjects of whom
88 were classiﬁed as having normal glucose metabolism (NGM),
21 as having impaired fasting glucose (IFG) and/or impaired glu-
ose tolerance (IGT), further referred to as with impaired glucose
etabolism (IGM), and 139 as having T2DM, 77 of which were
ewly diagnosed on the basis of results from an oral glucose toler-
nce test (OGTT) [12].
All subjects gave written informed consent. This study was
pproved by the Medical Ethical Committee of the Maastricht Uni-
ersity..2. Measurements
Height was measured with subjects standing upright against a
tadiometer andbodyweightwasmeasuredwith electronicweightlerosis 217 (2011) 263–267
scales with subjects wearing light indoor clothes without shoes.
BMI was calculated as weight divided by height squared. Waist cir-
cumferencewasmeasured in standing position at the levelmidway
between the lower rib and the spina iliaca anterior superior. Blood
pressure was measured twice in supine position and on the right
arm after 5min rest with an oscillometric precision device (Maxi
stable 3, Speidel & Keller). Smoking habits as well as the use of
medication were assessed by questionnaires.
Blood was collected after an overnight fast in pre-cooled EDTA
tubes. After centrifugation at 3000 rpm for 15min at 4 ◦C, plasma
aliquots were stored at −80 ◦C. Measurements of fasting plasma
triglycerides, total cholesterol, HDL cholesterol, apolipoprotein B,
glucose, HbA1c, creatinine, and insulinwere done as described pre-
viously [10]. LDL cholesterol was calculated with the Friedewald
formula [13].
Renal function was calculated by estimated glomeru-
lar ﬁltration rate (eGFR, in ml/min per 1.73m2) using the
Modiﬁcation of Diet in Renal Disease (MDRD) formula
([186 * (creatinine/88.4)−1.154 * age−0.203] * 0.742 if female) [14].
Coronary arterydiseasewasdeﬁnedas self-reportedmyocardial
infarction, coronary artery bypass surgery, percutaneous coronary
intervention or the presence of signs ofmyocardial infarction (Min-
nesota codes 1-1 or 1-2) or ischaemia (Minnessota codes 1-3, 1-4,
4-2, 4-3, 5-1, 5-2, 5-3 or 7-1) on a 12-lead electrocardiogram.
2.3. PCSK9 ELISA
PlasmaPCSK9 levelsweremeasuredwith the recently described
PCSK9 dual monoclonal antibody sandwich ELISA [11], with minor
modiﬁcations, including the use of a non-His-tagged recombinant
PCSK9 standard. The exact epitopes recognized by the antibodies
used in the ELISA are not known at this time. Human PCSK9 used
as a standard in the ELISA was cloned from a human liver cDNA
library with a resulting construct used to generate an HEK293 sta-
ble cell line over-expressing PCSK9. The cDNA sequence used did
not code for a His-tag. Cells were grown in serum free media, and
the secreted PCSK9proteinwas puriﬁed using an ion-exchange col-
umn followed by size-exclusion chromatography. Identity of the
protein was conﬁrmed by N-terminal sequencing, and purity was
judged to be greater than 95% based on SDS-PAGE followed by
Coomassie blue staining. ELISA wells were coated overnight with
anti-PCSK9monoclonal antibody at a concentration of 5g/ml. The
following day,wellswere aspirated,washed three timeswith assay
buffer (50mMHEPES,pH7.40, 150mMNaCl, 1%TritonX-100, 5mM
EDTA, 5mM EGTA), and blocked for 1h with TBS-casein blocking
buffer (Pierce). Next, 100l of non-His-tagged recombinant PCSK9
standards (varying concentrations of recombinant protein in assay
buffer) were added to the wells as a standard curve. Afterward,
serum samples were diluted 1:20 in assay buffer, added to their
respective wells, and the ELISA plate was incubated for 2h at room
temperature. Following aspiration, wells were washed three times
with assay buffer, and 100l of a 1:1000 dilution of conjugate
antibody (HRP-labeled anti-PCSK9 monoclonal antibody, 1mg/ml)
were added to the wells for a 1-h incubation at room temperature.
Following aspiration, wells were washed three times with TBST.
After the last aspiration of TBST, 100l of TMB development sub-
strate (Pierce) were added to the wells and allowed to incubate
for 30min at room temperature. The reaction was stopped with
an equal volume of 2N phosphoric acid, and plates were read at
450nm. SigmaPlot, version 8.0 was used for ﬁtting of the calibra-
tion curves. Serum samples were shipped on dry ice and stored at
−70 ◦C prior to analysis. The freeze–thaw stability was excellent
with >90% recovery even after four freeze–thaw cycles. The intra
assay coefﬁcient of variation (CV%) was 3.9–8.9% [15].
M.C.G.J. Brouwers et al. / Atherosc
F
r
2
e
D
T
r
s
l
f
s
r
o
b
t
p
g
l
a
t
t
(
3
o
w
a
c
f
f
i
c
w
1
i
a
w
v
3
(
w
n
v
wig. 1. Plasma PCSK9 levels in subjects with NGM, IGM and T2DM. Horizontal bars
epresent median values for each subgroup.
.4. Statistical analyses
Variableswith a skewed distribution, i.e. plasma insulin, triglyc-
rides and PCSK9 were log10 transformed prior to further analyses.
ifferences in general characteristics between individuals with
2DM or IGM versus with NGM were tested with linear or logistic
egressionanalyseswithadjustments forageandsex. Linear regres-
ion analyses were used to investigate the associations between
evels of PCSK9 and lipids in plasma. These analyses were adjusted
or age and sex andwere stratiﬁed according to glucosemetabolism
tatus. Possibledifference in the strengthof the associations (i.e. the
egression slopes) between PCSK9 and plasma lipids between IGM
r T2DM versus NGM were appreciated by testing the interaction
etween glucose metabolism status and PCSK9 in these associa-
ions. Interaction terms were considered statistically signiﬁcant at
< 0.10 level (this more liberal cut-off value is more appropriate
iven the lower sample size of stratiﬁed versus whole study popu-
ation analyses [16]), in concordancewith previous studies [17,18];
ll other comparisons were considered statistically signiﬁcant at
he conventional p<0.05 level.
All statistical analyses were carried out with the use of the Sta-
istical Package of Social Sciences (SPSS) version 16.0 for Windows
SPSS, Inc., Chicago, IL, USA).
. Results
General characteristics of the studypopulationacross categories
f glucose metabolism are shown in Table 1. Subjects with T2DM
ere more often men and older than subjects with NGM. After
djustments for age and sex, subjects with IGM and T2DM were
haracterized by increasingly higher levels of BMI, waist circum-
erence, blood pressure and use of anti-hypertensive medication,
asting glucose, HbA1c, insulin, triglycerides, lipid-lowering med-
cation and prior CHD, and lower levels of HDL-cholesterol. LDL
holesterol was signiﬁcantly lower in patients with T2DM but not
ith IGM when compared with subjects with NGM. Sixty-eight of
39 subjects with T2DM were treated with glucose lowering med-
cation, i.e. metformin (n=31), sulphonylurea derivatives (n=50),
carbose (n=1) and insulin (n=13). Two subjects classiﬁed as IGM
ere treated with a sulphonylurea derivative at the time of their
isit to our research unit.
.1. Relation of plasma PCSK9 levels with glucose tolerance
Median (interquartile) levels of plasma PCSK9 were 81.7ng/ml
65.1–102.7), 81.5 (67.6–100.4) and 79.6 (63.7–98.1) in subjects
ithNGM, IGMandT2DM, respectively (Fig. 1),whichwerenot sig-
iﬁcantly different (p=0.87 for IGM versus NGM; p=0.49 for T2DM
ersus NGM; age- and sex-adjusted). Additional adjustments for
aist circumference, plasma insulin levels, eGFR, use of lipid orlerosis 217 (2011) 263–267 265
glucose-lowering medication did not affect these outcomes (data
not shown).
Of note, HbA1c levels did not correlate with plasma PCSK9 lev-
els in the overall cohort (regression coefﬁcient beta =0.008, 95%CI:
−0.007 to 0.23, age- and sex-adjusted), nor in any subgroup (data
not shown).
3.2. Relation of plasma PCSK9 levels with lipid parameters
Plasma PCSK9 levels were signiﬁcantly associated with total
cholesterol, LDL cholesterol, non-HDL cholesterol, triglycerides and
apolipoprotein B levels in all glucose metabolism subgroups, after
adjustments for age and sex (Table 2). HDL cholesterol was not
associated with circulating PCSK9 levels in any group (Table 2).
Of interest, the strength of the associations – depicted by the
magnitude of the regression coefﬁcients, in particular for total
cholesterol, non-HDL cholesterol, triglycerides and apolipoprotein
B, increased as glucose metabolism deteriorated, such that they
were stronger among individuals with T2DM than with NGM.
Indeed, interaction terms were signiﬁcant for the relation of PCSK9
with non-HDL cholesterol and for the relation of PCSK9 with
apolipoproteinB levels betweensubjectswithNGMandwithT2DM
(p=0.05 and p=0.09, Fig. 2a and b, respectively). The interaction
term for the relation between PCSK9 and triglycerides between
NGM and T2DM was borderline signiﬁcant (p=0.10). None of the
associations investigated differed between subjects with IGM and
NGM, however. Of note, additional adjustments for use of lipid-
or glucose-lowering drugs or, alternatively, re-analysis with sub-
jects naïve to any lipid-lowering medication (n=253 NGM, n=106
T2DM), yielded similar outcomes (data not shown).
4. Discussion
The present study was conducted to investigate the role of
circulating PCSK9 levels in relation to diabetic dyslipidemia. For
this we measured plasma PCSK9 in a well-deﬁned cohort of sub-
jects with different degrees of glucose metabolism. Although the
degreeof glucosemetabolismper sewasnot associatedwithplasma
PCSK9 levels, it did appear to modify the relation between plasma
PCSK9 and plasma lipids, in particular non-HDL cholesterol and
apolipoprotein B.
The absence of a relation between PCSK9 and the degree of
derangement of glucose metabolism is in contrast with previous
large cohort studies reporting a signiﬁcant association between cir-
culating PCSK9 and plasma glucose levels [8,9]. It is unlikely that
this discrepancy is due to a lack of power in the current study, since
median plasma PCSK9 levels were almost identical between the
three groups of interest. Furthermore, HbA1c levels did not relate
to plasma PCSK9 levels in the overall cohort. A more likely expla-
nation could be the substantial proportion of subjects with newly
diagnosed T2DM (on the basis of results of anOGTT) included in the
present study. This may have resulted in a relatively narrow range
ofHbA1c levels and, consequently, failure to observe any difference
in PCSK9 levels between the three groups of interest.
Previous studies have mainly focused on the relation between
circulating PCSK9 levels and metabolic and lipid parameters in
healthy subjects [8,9,19]. The current report extends these data
by demonstrating that these relations, in particular for non-HDL
cholesterol and apolipoprotein B, may be modiﬁed by T2DM. It
should be noted that these interactions were just below the sta-
tistical threshold of p=0.10 for interaction and therefore deserve
further conﬁrmation in an independent cohort.
Another previously reported factor that modiﬁes the relation
between PCSK9 and plasma lipid levels is statin therapy [11]. It
is unlikely that the current observations can be accounted for by
266 M.C.G.J. Brouwers et al. / Atherosclerosis 217 (2011) 263–267
Table 1
General characteristics of study population.
NGM (n=288) IGM (n=121) T2DM(n=139)
Men/women, n 170/118 75/46 90/49*
Age (years) 58.6±7.4 59.9±6.6 61.1±6.2*
Current smoking (%) 20 18 18
BMI (kg/m2) 27.6±3.9 29.0±4.1† 30.3±4.7‡
Waist circumference (cm) 96.1±11.1 101.1±11.6‡ 104.8±11.5‡
Systolic blood pressure (mmHg) 135±18 144±20‡ 148±19‡
Diastolic blood pressure (mmHg) 80±8 84±10‡ 84±10‡
Antihypertensive medication (%) 26 40† 56‡
eGFR (ml/min per 1.73m2) 84.3±15.5 85.1±14.9 89.8±20.6‡
Fasting glucose (mmol/L) 5.3±0.4 5.9±0.5‡ 7.9±1.8‡
HbA1c (%) 5.6±0.4 5.8±0.4† 6.8±1.1‡
Glucose lowering therapy (%) 0 2 49
Insulin (pmol/L) 59.2 (41.0–68.0) 67.5 (46.0–100.8)‡ 86.5 (60–130)‡
Total cholesterol (mmol/L) 5.2±0.9 5.3±0.9 5.2±1.1
Non-HDL cholesterol (mmol/L) 4.0±0.9 4.1±0.9 4.1±1.2
HDL cholesterol (mmol/L) 1.3±0.4 1.2±0.3† 1.1±0.3‡
LDL cholesterol (mmol/L) 3.4±0.9 3.4±0.8 3.1±0.8†
Triglycerides (mmol/L) 1.2 (0.9–1.6) 1.7 (1.1–2.2)‡ 1.8 (1.2–2.4)‡
Apolipoprotein B (g/L) 1.1±0.2 1.2±0.2 1.1±0.3
Lipid-lowering medication (%) 12 17 24†
Coronary heart disease (%) 18 23 30†
Data are expressed as number or frequency (%), mean± standard deviation or median (interquartile range); all subjects stopped their lipid lowering medication two weeks
prior to blood withdrawal (see Section 2). NGM, normal glucose metabolism; IGM, impaired glucose metabolism, T2DM, type 2 diabetes; BMI, body mass index; eGFR,
estimated glomerular ﬁltration rate; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
* p<0.05, versus NGM.
† p<0.05, versus NGM, after adjustments for age and sex.
‡ p<0.001, versus NGM, after adjustments for age and sex.
Table 2
Associations between circulating PCSK9 with plasma lipids stratiﬁed by levels of glucose metabolism.
Dependent variables NGM
(n=288)
IGM
(n=121)
T2DM
(n=139)
ˇ 95%CI ˇ 95%CI ˇ 95%CI
Total cholesterol (mmo/L) 0.009 0.006; 0.013 0.010 0.004; 0.016 0.015 0.008; 0.022
LDL cholesterol (mmol/L) 0.007 0.004; 0.011 0.006 0.001; 0.012 0.011 0.005; 0.017
HDL cholesterol (mmol/L) 0.001 0.000; 0.002 −0.001 −0.003; 0.001 −0.001 −0.003; 0.001
Non-HDL cholesterol (mmol/L) 0.009 0.005; 0.012 0.011 0.004; 0.017 0.016 0.009; 0.022
Log10 triglycerides 0.001 0.000; 0.001 0.002 0.001; 0.004 0.002 0.001; 0.003
Apolipoprotein B (g/L) 0.002 0.001; 0.003 0.003 0.001; 0.004 0.004 0.002; 0.005
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abbreviations: ˇ, linear regression coefﬁcient; indicates change in dependent variabl
GM, impaired glucose metabolism; T2DM, type 2 diabetes mellitus; LDL, low-dens
nalyses were adjusted for age and sex.
tatin use, since subjects included in the current study were with-
rawn from any lipid lowering medication two weeks prior their
isit. Furthermore, re-analysis with only subjects who had never
een treated with lipid-lowering medication yielded very similar
ig. 2. Unadjusted associations betweenPCSK9andnon-HDL cholesterol (panel A) andapo
re age- and sex-adjusted.ng/ml increase in PCSK9; CI, conﬁdence interval; NGM, normal glucose metabolism;
oprotein; HDL, high-density lipoprotein.
results. Finally, statin therapy decreases the strength of the asso-
ciation between PCSK9 and total cholesterol, LDL cholesterol and
triglycerides [11] whereas, in the present study, these associations
appeared to be stronger among individuals with T2DM.
lipoproteinB (panel B) in individualswithNGMandT2DM; *p-values for interaction
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The expression of the LDL receptor is not only mediated by
CSK9, but also by several other factors, such as thyroid hormone
20]. Of interest, Bakker and colleagues have shown that the rela-
ion between plasma thyrotropin levels and LDL cholesterol is
odiﬁed by the degree of insulin resistance, i.e. the association
f thyrotropin with LDL cholesterol levels is stronger as insulin
esistance increases [21]. These observations therefore appear to
e in concordance with our current results that T2DM may act as
n effect modiﬁer in the relation between PCSK9 and lipoprotein
etabolism.
Although this study should be regarded as hypothesis gener-
ting and the exact mechanism for this interaction remains to be
lucidated, one could speculate on its pathogenesis. For instance, it
an be anticipated that VLDL overproduction, as documented in
2DM [2,3], does not have substantial consequences on plasma
ipid levels as long as their clearance is not impaired. However,
hen there is an additional low expression of LDL receptors, due
o among others high levels of PCSK9 [7], it can be expected that
hese defects act synergistically on plasma lipid levels resulting in a
teeper slope for the relation between PCSK9 and non-HDL choles-
erol/apolipoprotein B, as observed in T2DM. The lack of interaction
f LDL cholesterol levels with T2DM in the present study may be
xplained by the fact that LDL cholesterol levels do not necessar-
ly reﬂect LDL particle number – which is the actual ligand for
he LDL receptor – in particular in the high triglycerides range
>1.5mmol/L) [22]. Previous studies have shown that apolipopro-
ein B and non-HDL cholesterol are better indices of LDL particle
umber than plasma LDL cholesterol levels [22].
Management of diabetic dyslipidemia currently consists of life
tyle modiﬁcations, ﬁbrates and statin therapy [23]. Of interest, the
atter therapy has consistently been associated with an apparently
aradoxical increase in plasma PCSK9 levels, also in T2DM [24,25],
hereas conﬂicting results have been obtained for ﬁbrate therapy
25,26]. These observations suggest that additional treatment with
PCSK9antagonist,which isunder currentdevelopment [27], could
ork in a synergistic manner with statin therapy to further reduce
lasma lipid levels.Whether patientswith T2DM could also beneﬁt
rom PCSK9 antagonizing therapy needs to be further investigated.
In conclusion, the present study clearly demonstrates that the
egree of glucose intolerance is not associated with plasma PCSK9
evels. It may, however, modify the relation between circulating
CSK9 and plasma lipid levels, as reﬂected by a stronger relation
etween PCSK9 with non-HDL cholesterol and apolipoprotein B
evels in patients with T2DM. These epidemiological observations
hould be regarded as hypothesis generating for further studies
imed at elucidating the role of PCSK9 in the pathogenesis and
reatment of diabetic dyslipidemia.
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